Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

BMC Pulmonary Medicine

Table 3 0–24 h wmFEV₁ and trough FEV₁ by GOLD subgroup (ITT population)

Endpoint	UMEC/VI 62.5/25 mcg (N = 358)	FP/SAL 500/50 mcg (N = 358)
0–24 h wmFEV₁ on Day 84, L, change from baseline
GOLD B ^a,b
n	184	189
mean (SD)	0.181 (0.2476)	0.096 (0.2230)
GOLD D ^b,c
n	148	148
mean (SD)	0.152 (0.2111)	0.071 (0.2038)
Trough FEV₁ on Day 85, L, change from baseline
GOLD B ^a,b
n	185	189
mean (SD)	0.162 (0.2661)	0.070 (0.2340)
GOLD D ^b,c
n	148	149
mean (SD)	0.143 (0.2067)	0.049 (0.2160)

Descriptive analyses of change from baseline in 0–24 h wmFEV₁ on Day 84 and in trough FEV₁ on Day 85 by GOLD subgroup
FEV₁ forced expiratory volume in 1 s, FP/SAL fluticasone propionate/salmeterol, GOLD Global Initiative for Chronic Obstructive Lung Disease™, ITT intent-to-treat, SD standard deviation, UMEC umeclidinium, VI vilanterol, wm weighted mean
^aFEV₁ ≥ 50 % to <80 % predicted; ^bAll but three patients fulfilled the exclusion criterion regarding no exacerbations in the past year—no further details of exacerbation history were collected; ^cFEV₁ ≥ 30 % to <50 % predicted

ISSN: 1471-2466